Opinion|Videos|July 31, 2024
BRIGHTSTAR: Local Consolidative Therapy with Brigatinib in TKI-naïve ALK-rearranged Metastatic NSCLC
Laila Gharzai, MD, discusses findings from the BRIGHTSTAR trial which evaluated brigatinib in TKI-naïve patients with ALK-rearranged metastatic non–small cell lung cancer.
Advertisement
Episodes in this series
Advertisement
Related to this article
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Matthew Lee, MD, shares his key takeaway from the first disclosure of BG-C477 data in advanced NSCLC.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.
Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population.
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.
Findings from the phase 1 KANDLELIT-001 study support further investigation of calderasib plus pembrolizumab in KRAS G12C-mutated metastatic NSCLC.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prior Regimen Did Not Affect Daraxonrasib Benefit in Pretreated Pancreatic Cancer
2
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
3
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
4
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
5